# Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

> **NCT00780663** · PHASE2 · COMPLETED · sponsor: **Cylene Pharmaceuticals** · enrollment: 25 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Carcinoid Tumor

## Interventions

- **DRUG:** Quarfloxin

## Key facts

- **NCT ID:** NCT00780663
- **Lead sponsor:** Cylene Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2011-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780663, "Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00780663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*